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Corneal Confocal Microscopy detects improvements in small nerve fibres in subjects with Latent Autoimmune Diabetes in Adults with enhanced glycaemic control

Latent Autoimmune Diabetes in Adults (LADA) is often misdiagnosed, and a prolonged period of poor glycaemic control may increase the risk of microvascular complications. We aimed to evaluate a cohort of subjects with LADA over 1 year and undertake detailed assessment of measures of large and small fibre neuropathy to assess the natural history of diabetic neuropathy. 
We have undertaken a detailed assessment of neuropathy in control subjects (C) (n=14), subjects with type 2 DM (T2DM) (n=14) and LADA (n=14) by quantifying: neuropathy disability score (NDS), peroneal and sural nerve conduction velocity and amplitude (PMNCV, PMNAmp, SSNCV, SSNAmp), cold threshold (CT), warm threshold (WT), corneal nerve fibre density (CNFD), branch density (CNBD) and fibre length (CNFL) at baseline and 1 year follow up.
There was no significant difference in age (50.0±2.9 vs 54.0±6.5 vs 50.1±13.7 years, P=NS), duration of diabetes (T2DM: 5.3±3.9 vs LADA: 12.5±10.6 years, P=NS), blood pressure, total cholesterol, HDL, triglycerides and eGFR. HbA1c (39.7±2.8 vs 53.4±7.3 vs 83.8±25.3 mmol/mol, P<0.0001) was higher and BMI (29.4±5.2 vs 31.0±4.5 vs 26.5±4.6 kg/m2, P=0.01) was lower in LADA compared to T2DM. There were no significant differences in NDS (0.3±0.6 vs 1.6±1.7 vs 3.8±3.3, P=NS), PMNCV (49.2±4.2 vs 44.3±8.8 vs 40.7±7.6 m/s, P=NS), PMNAmp (5.5±1.9 vs 4.0±2.1 vs 3.2±2.2 mV, P=NS), SSNCV (50.5±3.5 vs 47.8±5.1 vs 43.4±5.6 m/s, P=NS), SSNAmp (17.7±7.1 vs 12.6±7.6 vs 11.0±5.8 µV, P=NS), WT (37.0±3.1 vs 40.9±3.6 vs 42.4±5.0 ˚C, P=NS), CT (28.9±1.2 vs 27.0±3.2 vs 24.1±4.7 ˚C, P=NS)  between LADA and T2DM. However, CNFL (16.9±4.6 vs 17.1±4.7 vs 11.7±3.3 mm/mm2, P=0.003) and CNBD (37.8±18.0 vs 45.5±26.4 vs 21.0±10.6 no/mm2, P=0.008) were significantly lower with no difference in CNFD (29.0±9.1 vs 28.8±9.8 vs 18.8±7.1 no/mm2, P=NS) between LADA and T2DM. 
Comparing baseline to 1 year follow up, there were no changes in BMI, lipids, NDS, CT, WT and electrophysiology in C, T2DM and LADA. HbA1c, CNFD, CNBD and CNFL did not differ in C and T2DM. However, HbA1c was lower and approached significance (83.8±25.3 vs 70.0±17.4 mmol/mol, P=0.07) with a higher CNBD (21.0±10.6 vs 34.8±16.3 no/mm2, P=0.005) and CNFL (11.7±3.3 vs 14.3±4.0 mm/mm2, P=0.02) with no change in CNFD (18.8±7.1 vs 22.3±5.9 no/mm2, P=NS) in LADA. 
Subjects with LADA have a significant small fibre neuropathy due to poorer glycaemic control and enhanced glycaemic control improves neuropathy measured using CCM. CCM not only detects but also monitors progression of small fibre neuropathy and provides the ideal surrogate marker in therapeutic trials of diabetic neuropathy.


